ReviewEuropean respiratory review : an official journal of the European Respiratory Society2020
Bronchoscopic intratumoural therapies for non-small cell lung cancer.
Review in European respiratory review : an official journal of the European Respiratory Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 35 citations in OpenAlex.
- Bronchoscopic Ablation and Intratumoral Therapies for Lung Cancer: Expanding Local Treatment Beyond Surgical Resection.Cancers · 2026Review
- Advanced Bronchoscopic Approaches to Peripheral Pulmonary Lesions: a Narrative Review of Current and Emerging Techniques.Pulmonary therapy · 2026Review
- Fracking in Tumors: A Key Drug Transport Mechanism.Annals of biomedical engineering · 2026Article
- Endobronchial Intratumoral Immuno- and Gene Therapies in Lung Cancer: Mechanisms of Local Delivery, Systemic Immune Effects, and Global Feasibility.International journal of molecular sciences · 2026Review
- Importance of the delivery route for the tolerability and efficacy of immunomodulatory agents for lung cancer.Scientific reports · 2026Article
- Article
- A Case of Advanced Lung Adenocarcinoma Successfully Treated by Intratumoral Injection of Tirelizumab Under Tracheoscopy.Cancer reports (Hoboken, N.J.) · 2025Article
- Active microgel particle swarms for intrabronchial targeted delivery.Science advances · 2025Article
- Robotic-assisted bronchoscopy-advancing lung cancer management.Frontiers in surgery · 2025Review
- Article
- Robotic-assisted bronchoscopy: a narrative review of systems.Journal of thoracic disease · 2024Review
- Interventional bronchoscopy in lung cancer treatment.Breathe (Sheffield, England) · 2024Review
- Initial Safety and Feasibility Results From a Phase 1, Diagnose-and-Treat Trial of Neoadjuvant Intratumoral Cisplatin for Stage IV NSCLC.JTO clinical and research reports · 2024Article
- Clinical Applications of Endobronchial Ultrasound (EBUS) Scope: Challenges and Opportunities.Diagnostics (Basel, Switzerland) · 2023Review
- Metastatic lymph node targeted CTLA4 blockade: a potent intervention for local and distant metastases with minimal ICI-induced pneumonia.Journal of experimental & clinical cancer research : CR · 2023Article
- Robotic Bronchoscopy: Review of Three Systems.Life (Basel, Switzerland) · 2023Review
- Endoscopic Technologies for Peripheral Pulmonary Lesions: From Diagnosis to Therapy.Life (Basel, Switzerland) · 2023Review
- Real-World Impact of Robotic-Assisted Bronchoscopy on the Staging and Diagnosis of Lung Cancer: The Shape of Current and Potential Opportunities.Pragmatic and observational research · 2023Review
- Overview of malignant central airway obstruction.Mediastinum (Hong Kong, China) · 2023Review
- Efficacy of bronchoscopic intratumoral injection of endostar and cisplatin in lung squamous cell carcinoma patients underwent conventional chemoradiotherapy.Open medicine (Warsaw, Poland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past decade has brought remarkable improvements in the treatment of non-small cell lung cancer (NSCLC) with novel therapies, such as immune checkpoint inhibitors, although response rates remain suboptimal. Direct intratumoural injection of therapeutic agents
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.